South African National Department of Health Selects Mylan as a Leading Supplier for 2015/2018 Antiretroviral Tender
JOHANNESBURG and PITTSBURGH, Dec. 31, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary in India, Mylan Laboratories Ltd., a leading manufacturer of antiretroviral (ARV) drugs, has been selected, through its South African-based subsidiary Mylan (Proprietary) Limited, as one of the leading suppliers of ARV medications to the South African National Department of Health for the tender period April 1, 2015 to March 31, 2018.
Video - http://youtu.be/RiFbPU98AHo
Logo - http://photos.prnewswire.com/prnh/20140423/77793
As a part of this award, Mylan will supply the South African Government with triple therapy fixed dose combination (FDC) treatments. Mylan was previously selected as a leading supplier for the 2013/2014 tender and is pleased to continue its support of the Government's initiative to increase the number of patients on triple therapy FDC treatment regimens in South Africa, as such regimens can simplify treatment and improve patient adherence.
Mylan CEO Heather Bresch commented, "Mylan's selection by the South African Department of Health as a leading supplier of ARVs reinforces our longstanding commitment to fighting HIV/AIDS in both South Africa and around the world. We are proud of our progress to date in stemming the tide of the disease with approximately 40% of those being treated in the developing world today depending on our ARV products, but with more than 35 million people affected globally there is more work to be done. This tender supports our mission to provide the world's 7 billion people access to high quality medicine, including affordable ARVs, and we look forward to working with the South African Government on this important effort."
Guillaume van Niekerk, Mylan South Africa managing director and vice president, added, "We applaud the South African Government's tremendous efforts the past two years in increasing the number of individuals who have been tested and treated for HIV/AIDS. Mylan South Africa looks forward to partnering with the Government again and continuing our role as a leading ARV supplier. This new tender represents our ability to reliably supply the South Africa market with high quality, affordable ARV medications, and our dedication to making a positive change in the local HIV/AIDS community."
Mylan supplies ARV drugs to more than 100 countries around the world. In 2012, Mylan entered the South African market with a comprehensive portfolio of ARV medications, consisting of first- and second-line adult and pediatric therapies, including several dual and triple FDCs.
Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,300 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 25,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. Learn more at mylan.com
This press release may contain "forward-looking statements," including statements about the Company's future operations, planned activities, anticipated growth, market opportunities, strategies, competition, and other expectations. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the effect of any changes in customer and supplier relationships and customer purchasing patterns; changes in industry regulations and relationships with government authorities; changes in third-party relationships; the impacts of competition; changes in economic and financial conditions of the Company's business; uncertainties and matters beyond the control of management; and the other risks detailed in the company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any statements herein for revisions or changes after the date of this release.
Share this article